4.8 Article

Somatic SETBP1 mutations in myeloid malignancies

期刊

NATURE GENETICS
卷 45, 期 8, 页码 942-U298

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ng.2696

关键词

-

资金

  1. US National Institutes of Health (NIH) [RO1 HL-082983, U54 RR019391, K24 HL-077522, RO1 CA-143193]
  2. AA & MDS International Foundation
  3. Robert Duggan Charitable Fund
  4. Scott Hamilton CARES grant
  5. Ministry of Health, Labor and Welfare of Japan
  6. KAKENHI [23249052, 22134006, 21790907]
  7. Japan Society for the Promotion of Science (JSPS)
  8. Council for Science and Technology Policy (CSTP), Taiwan [NHRI-EX100-10003NI]
  9. Uniformed Services University of the Health Sciences Pediatrics [KM86GI]
  10. Grants-in-Aid for Scientific Research [23249052, 22134006, 24659458, 25670446, 24791054, 24390262, 24390242] Funding Source: KAKEN

向作者/读者索取更多资源

Here we report whole-exome sequencing of individuals with various myeloid malignancies and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia (aCML)(1). Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in Schinzel-Giedion syndrome (SGS)(2), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases. These results from deep sequencing demonstrate a higher mutational detection rate than reported with conventional sequencing methodology(3-5). Mutant cases were associated with advanced age and monosomy 7/deletion 7q (-7/del(7q)) constituting poor prognostic factors. Analysis of serially collected samples indicated that SETBP1 mutations were acquired during leukemic evolution. Transduction with mutant Setbp1 led to the immortalization of mouse myeloid progenitors that showed enhanced proliferative capacity compared to cells transduced with wild-type Setbp1. Somatic mutations of SETBP1 seem to cause gain of function, are associated with myeloid leukemic transformation and convey poor prognosis in myelodysplastic syndromes (MDS) and CMML.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据